US Approves Vagus Nerve Stimulation for Arthritis Treatment

The US Food and Drug Administration (FDA) has granted approval for a vagus nerve stimulation device aimed at treating rheumatoid arthritis. This marks the first time a device like this has been authorized for an autoimmune disorder, opening possibilities for broader medical uses.

The small, tablet-sized device is surgically placed alongside the vagus nerve, which consists of nerve fibers connecting the brain to vital organs. It automatically administers electrical pulses that stimulate the nerves and help reduce inflammation for up to a decade.

Rheumatoid arthritis, similar to other autoimmune disorders, leads to excessive inflammation, causing the body to mistakenly attack its own tissues, resulting in pain, swelling, and potential organ damage. Treatment typically involves strong anti-inflammatory medications that suppress the immune system, increasing vulnerabilities to infections and cancer. Nearly 75% of rheumatoid arthritis patients express dissatisfaction with current therapies and have discontinued them due to adverse side effects.

In clinical trials, 242 participants with moderate to severe rheumatoid arthritis were tested, showing that about 35% of those receiving vagus nerve stimulation for 12 weeks experienced at least a 20% reduction in symptoms compared to only 24% in the placebo group. Less than 2% faced serious side effects, and none developed severe infections.

“Utilizing a safe computer chip as an alternative to expensive, minimally effective medications with significant side effects presents an appealing option for many patients,” remarked Kevin Tracy from the Feinstein Institute of Medicine in New York. He originated the device approximately two decades ago while working with Setpoint Medical, a US medical technology firm that is no longer operational.

This approval signifies a pivotal advancement toward potentially treating various inflammation-related ailments, including heart failure, diabetes, and neurodegenerative disorders such as Parkinson’s disease, through vagus nerve stimulation. Stavros Zanos at the Feinstein Medical Institute emphasizes that SetPoint Medical’s device is already being evaluated in clinical trials for conditions like multiple sclerosis and inflammatory bowel disease.